Jobs

The pharma industry found it harder to fill digitalization vacancies in Q1 2022

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

An increase in the number of days that related job ads stayed online indicates the required skillset for these roles has become harder to find in the past year.

Powered by 

Digitalization related jobs that were closed during Q1 2022 had been online for an average of 34 days when they were taken offline. 

This was an increase compared to the equivalent figure a year earlier, indicating that the required skillset for these roles has become harder to find in the past year. 

Digitalization is one of the topics that GlobalData, our parent company and from whom the data for this article is taken, have identified as being a key disruptive technology force facing companies in the coming years. Companies that excel and invest in these areas now are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

On a regional level, these roles were hardest to fill in Europe, with related jobs that were taken offline in Q1 2022 having been online for an average of 35.1 days. 

The next most difficult place to fill these roles was found to be Asia-Pacific, while North America was in third place. 

At the opposite end of the scale, jobs were filled fastest in the Middle East and Africa, with adverts taken offline after 12 days on average.

While the pharmaceutical industry found it harder to fill these roles in the latest quarter, these companies also found it harder to recruit digitalization jobs than the wider market, with ads online for 13.3% more time on average compared to similar jobs across the entire jobs market. 

GlobalData's job analytics database tracks the daily hiring patterns of thousands of companies across the world, drawing in jobs as they're posted and tagging them with additional layers of data on everything from the seniority of each position to whether a job is linked to wider industry trends.

Go to article: Home | Genomic projects exploit scaleGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article: CommentGo to article: Disappointing results signal setbacks for Alzheimer’s treatmentsGo to article: Heart failure: charting the clinical trial landscape in the past decadeGo to article: Russia’s focus on domestic pharma production could shield it from sanctionsGo to article: Delayed EMA approval: improved safety or lack of access to therapeutics?Go to article: CMOs and US Government invest in continuous manufacturingGo to article: BaxterGo to article: CSafe GlobalGo to article: NiproGo to article: In DepthGo to article: Genomic projects exploit scale as clinical applications play catch-upGo to article: Tracing the rise of orphan drug designations over almost 40 yearsGo to article: How much does it hurt—measuring pain in clinical trialsGo to article: Neglected tropical diseases: non-profits lead the way as private sectors lagsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing-JulyGo to article: Pfeiffer VacuumGo to article: Biolife SolutionsGo to article: In DataGo to article: Supply chain & logistics innovation among pharma companiesGo to article: Hiring boom in pharmaceutical industry IoT rolesGo to article: Regenerative medicine deals decreased in the pharma industryGo to article: Digitalization jobs in the pharmaceutical industryGo to article: EventsGo to article: Next issue